Enlighting the Shadow for Advanced Hepatocellular Carcinoma: Immunotherapy with Immune Checkpoint Inhibitors
Hepatocellular carcinoma has still been one of the cancer with increasing incidence and highest mortality rate in the world. Although many new promising developments have been defined in hepatocarcinogenesis, with a short survival the treatment of patients with advanced hepatocellular carcinoma is an emerging issue. On the recent decade, only one anti-angiogenic agent sorafenib improved overall survival with costing a hardly manageable toxicity. Novel immunotherapeutic agents, especially immune checkpoint inhibitors are on the edge of more effective but less toxic treatments for these patients. In this article the activity of immune checkpoint inhibitors, anti-CTLA-4 and anti-PD1 antibodies for the treatment of patients with advanced hepatocellular cancer will be reviewed.
KeywordsHepatocellular carcinoma Immunotherapy Immune checkpoint inhibitors Anti-CTLA-4 Anti-PD1
- 1.International Agency for Research on Cancer. GLOBOCAN. Estimated Global Cancer Incidence, Mortality and Prevalence Worldwide in. 2012:2012. http://globocan.iarc.fr/Pages/fact_sheets_population.aspx. Accessed August 04, 2017
- 4.Subramanian S, et al. A review of hepatocellular carcinoma (HCC) staging systems. Chin Clin Oncol. 2013;2:33.Google Scholar
- 7.Cheng A-L et al. Phase III trial of lenvatinib (LEN) vs sorafenib (SOR) in first-line treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC). J Clin Oncol 35, 2017 (suppl; abstr 4001).Google Scholar
- 21.El-Khoueiry AB, et al. Phase 1/2 safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma: interim analysis of the CheckMate 040 dose-escalation study. Poster presentation at ASCO. 2016; poster 4012Google Scholar
- 22.Sangro B, Melero I, Yau T et al. Safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma: interim analysis of dose-expansion cohorts from the phase 1/2 checkmate 040 study. In:Presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO); June 3–7, 2016; Chicago, IL, USA, poster 4078.Google Scholar